Bladder Cancer: Diagnosis and Evaluation: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 158: | Line 158: | ||
=== <span style="color:#ff0000">Other </span> === | === <span style="color:#ff0000">Other </span> === | ||
* '''The diagnosis of bladder cancer is confirmed by direct visualization of the tumor with cystoscopy and endoscopic excision using TURBT''' | |||
** '''2016 AUA NMIBC Guidelines: Surgeons may proceed directly to TURBT [without prior cystoscopy] should CT or MRI reveal a bladder lesion during the evaluation of hematuria.''' | |||
==== Cystoscopy ==== | |||
* Non–muscle-invasive cancers can be very large because of lack of genetic alterations required for invasion. Likewise, invasive tumors can be quite small if early genetic changes occur within the tumor cell, allowing for an invasive phenotype | |||
* T1 tumors are usually papillary and often have a narrow stalk; a nodular or sessile appearance suggests deeper invasion | |||
* Methods to reduce pain associated with cystoscopy based on randomized trials (2): | |||
*# Flexible cystoscope | |||
*# “bag squeeze” technique (applying pressure to the saline bag during cystoscopy at the level of the membranous / prostatic urethra) | |||
** '''<span style="color:#ff0000">Narrow band imaging (NBI)</span>''' | ===== '''<span style="color:#ff0000">Enhanced cystoscopy</span>''' ===== | ||
====== '''<span style="color:#ff0000">Fluorescent (blue light) cystoscopy[https://www.ncbi.nlm.nih.gov/pubmed/17499283][https://www.ncbi.nlm.nih.gov/pubmed/17499291]</span>''' ====== | |||
* '''<span style="color:#ff0000">A photosensitizing agent, 5-aminolevulinic acid (ALA) or hexyl aminolevulinic acid (HAL), is instilled into the bladder</span>''' before the procedure for 1-4 hours | |||
** HAL is approved for use both in Europe and the United States, but currently does not have Health Canada approval | |||
* '''<span style="color:#ff0000">The photosensitizing agent is metabolized to protoporphyrn IX by tumor cells,</span> emitting a red fluorescence under blue light''' | |||
* '''<span style="color:#ff0000">Blue light cystoscopy improves detection of both small papillary tumors and CIS</span>''' | |||
** Sensitivity for CIS 87% compared to 83% with white light | |||
** '''Relatively high false-positive rate''' | |||
* Also reduces the rate of residual tumour by 20% compared to white light cystoscopy | |||
* '''<span style="color:#ff00ff">NCT02560584</span>''' | |||
** Population: 304 patients with a history of multiple, recurrent or high grade bladder tumors undergoing first surveillance cystoscopy | |||
** Randomized to white light +/- blue light flexible cystoscopy | |||
** Primary outcome: proportion of patients with histologically confirmed malignancy that was detected only by blue light and not by white light flexible cystoscopy in the surveillance setting. | |||
** Results: | |||
*** 103/403 patients found to have suspicious lesions on flexible cystoscopy and referred to operating room. | |||
*** 63/103 found to have malignancy | |||
**** 20% of recurrences seen only with blue-light flexible cystoscopy | |||
** [https://pubmed.ncbi.nlm.nih.gov/29203268/ Daneshmand, Siamak, et al.] "Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study." ''The Journal of urology'' 199.5 (2018): 1158-1165. | |||
* '''Prospective studies have shown that blue light cystoscopy decreases recurrence rates, despite a trend in decreasing progression rates and prolong time to progression, current data is inconclusive, and impact on oncologic outcomes other than recurrence remains unclear''' | |||
** '''Most clinical trials testing BLC have not used single dose chemotherapy at the time of TURBT, so the impact of combining both interventions remains uncertain.''' | |||
* '''<span style="color:#ff0000">Guideline perspective on role of fluorescent (blue light) cystoscopy:</span>''' | |||
** '''CUA: can increase tumour detection at first TURBT and reduce recurrence risk.''' | |||
** '''<span style="color:#ff0000">AUA:</span> in a patient with NMIBC, blue light cystoscopy <span style="color:#ff0000">should be offered at the time of TURBT, if available,</span> to increase detection and decrease recurrence''' | |||
====== '''<span style="color:#ff0000">Narrow band imaging (NBI)</span>''' ====== | |||
*Filters white light into blue and green wavelengths. | |||
*'''The light penetrates the superficial bladder tissues and is <span style="color:#ff0000">strongly absorbed by hemoglobin</span>, enhancing the contrast between normal urothelium and the blood vessels in the highly vascular malignant tumours.''' | |||
*Does not require bladder instillation, unlike blue-light cystoscopy | |||
*'''Improves tumour detection, but the prognostic impact remains unknown''' | |||
**Herr and Donat (2008) performed white light and NBI cystoscopy in 427 consecutive patients with a history of NMIBC. Of the 103 patients with a tumor recurrence, 56% had additional tumors identified with NBI compared with use of WLC, and in 12% of patients, the recurrent tumor was found only with NBI. For WLC and NBI cystoscopy, the overall sensitivities were 87% and 100% and the overall specificities were 85% and 82%, respectively | |||
*'''<span style="color:#ff0000">Guideline perspective on role of NBI cystoscopy:</span>''' | |||
**'''<span style="color:#ff0000">CUA: NBI improves tumour detection, but the prognostic impact remains unknown</span>''' | |||
**'''<span style="color:#ff0000">AUA:</span> in a patient with NMIBC, <span style="color:#ff0000">consider the use of NBI to increase detection and decrease recurrence</span>''' | |||
==== TURBT ==== | |||
* Patients found to have a bladder tumour should undergo initial TURBT for diagnostic confirmation and pathological evaluation | |||
*'''An adequate TURBT requires complete resection of all visible tumor with adequate sampling of the bladder to assess the depth of invasion''' | |||
** '''Initial TURBT aims for complete tumour resection + sampling of the underlying detrusor muscle''' as the first step of curative-intent treatment of NMIBC | |||
*** Sampling of detrusor muscle is an important quality indicator (in tumours other than PUNLMP, LG Ta, and CIS), and its absence is associated with risk of under-staging, residual disease, and recurrence | |||
*** '''Patients with presumed TaLG or CIS might be spared from muscle sampling at initial TURBT''' | |||
== Clinical Staging in Patients Diagnosed with Bladder Cancer == | == Clinical Staging in Patients Diagnosed with Bladder Cancer == | ||